Financial reports
20-F
2023 FY
Annual report (foreign)
20 Feb 24
20-F
2022 FY
Annual report (foreign)
21 Feb 23
20-F
2021 FY
Annual report (foreign)
22 Feb 22
20-F
2020 FY
Annual report (foreign)
16 Feb 21
20-F
2019 FY
Annual report (foreign)
3 Mar 20
20-F
2018 FY
Annual report (foreign)
5 Mar 19
20-F
2017 FY
Annual report (foreign)
6 Mar 18
20-F
2016 FY
Annual report (foreign)
7 Mar 17
20-F
2015 FY
Annual report (foreign)
8 Mar 16
20-F
2014 FY
Annual report (foreign)
10 Mar 15
Current reports
6-K
1ST Quarter Results
25 Apr 24
6-K
Result of Agm
11 Apr 24
6-K
Astrazeneca Increases 2024 Dividend by 7%
11 Apr 24
6-K
Enhertu Approved In Us for HER2+ Solid Tumours
8 Apr 24
6-K
Imfinzi Improved Os & PFS In Limited-stage SCLC
5 Apr 24
6-K
Total Voting Rights
2 Apr 24
6-K
Voydeya Approved In Us
2 Apr 24
6-K
Fda Accepts Dato-dxd Bla for Breast Cancer
2 Apr 24
6-K
Ultomiris Approved In the Us for Nmosd
25 Mar 24
6-K
Current report (foreign)
19 Mar 24
Registration and prospectus
F-3ASR
Automatic shelf registration (foreign)
19 Mar 24
8-A12B
Registration of securities on exchange
5 Mar 24
424B2
Prospectus for primary offering
23 Feb 24
FWP
Free writing prospectus
21 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
21 Feb 24
424B2
Prospectus for primary offering
21 Feb 24
S-8
Registration of securities for employees
20 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
20 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
14 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
19 Jan 24
Other
CERT
Certification of approval for exchange listing
6 Mar 24
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
20 Feb 24
CERT
Certification of approval for exchange listing
15 Mar 23
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
21 Feb 23
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
22 Feb 22
CERT
Certification of approval for exchange listing
3 Jun 21
EFFECT
Notice of effectiveness
13 Apr 21
CORRESP
Correspondence with SEC
8 Apr 21
UPLOAD
Letter from SEC
1 Mar 21
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
16 Feb 21
Ownership
SC 13G/A
ADC Therapeutics SA
12 Feb 24
SC 13G/A
BlackRock Inc.
24 Jan 24
SC 13D/A
Cellectis S.A.
16 Nov 23
144
Notice of proposed sale of securities
13 Nov 23
SC 13D
Cellectis S.A.
9 Nov 23
11-K
Annual report of employee stock purchases
28 Jun 23
SC 13G/A
Aridis Pharmaceuticals, Inc.
10 Feb 23
SC 13G/A
PIERIS PHARMACEUTICALS, INC.
10 Feb 23
SC 13G/A
BlackRock Inc.
24 Jan 23
SC 13G
BlackRock Inc.
8 Jul 22